Genentech panel advises against Roche's takeover bid

02/23/2009 | Financial Times (free content) · San Francisco Chronicle

A three-member committee of Genentech directors unanimously recommended that shareholders reject Roche's $42 billion buyout bid, saying the offer "substantially undervalues" the biotech company. "We are disappointed that Roche has chosen not to consider an appropriate price range for Genentech's minority shares or to constructively negotiate with our committee, and we must recommend that stockholders not tender their shares as a result," they wrote in a statement.

View Full Article in:

Financial Times (free content) · San Francisco Chronicle

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC